Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

435.71 -10.06 (-2.26%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

74 75 Next >

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

December 05, 2024

Via The Motley Fool

FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program ↗

December 04, 2024

CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

December 04, 2024

Via Benzinga

It’s Been A Tough Month For Healthcare Stocks ↗

December 02, 2024

It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.

Via Talk Markets

Topics ETFs Stocks / Equities

Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. ↗

November 28, 2024

Via The Motley Fool

Looking Into Vertex Pharmaceuticals's Recent Short Interest ↗

November 25, 2024

Via Benzinga

Got $500? 1 Biotech Stock to Buy and Hold Forever ↗

November 22, 2024

Via The Motley Fool

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics ↗

November 18, 2024

Via Benzinga

Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? ↗

November 24, 2024

Via The Motley Fool

3 Growth Stocks You Can Buy Right Now Without Any Hesitation ↗

November 18, 2024

Via The Motley Fool

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More ↗

November 16, 2024

Via The Motley Fool

Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity ↗

November 13, 2024

Regulators are reviewing what could become a multi-billion-dollar drug.

Via The Motley Fool

Biotech Stocks Are Rallying: What Is Your Playbook? ↗

November 11, 2024

If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers.

Via Talk Markets

Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity ↗

November 05, 2024

Via Benzinga

Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts ↗

November 05, 2024

Via Benzinga

Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points ↗

November 09, 2024

Meta just forged a new base. All five stocks are on the IBD Leaderboard list.

Via Investor's Business Daily

Topics Stocks

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review ↗

November 08, 2024

A Fed rate cut and a slew of big earnings reports filled out a busy week.

Via Investor's Business Daily

Topics Economy Government

2 Biotech Stocks You Can Buy Hand Over Fist This Month ↗

November 08, 2024

Both stocks have made significant breakthroughs.

Via The Motley Fool

Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday? ↗

November 05, 2024

Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes for the 47th president.

Via Benzinga

5 Top Stocks to Buy in November ↗

November 05, 2024

From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know where to look.

Via The Motley Fool

My 2 Favorite Growth Stocks to Buy Hand Over Fist in November ↗

November 05, 2024

The sky's the limit for these stocks.

Via The Motley Fool

Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript ↗

November 04, 2024

VRTX earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms ↗

November 04, 2024

Vertex Pharmaceuticals beat third-quarter expectations on Monday. The company also raised its sales outlook.

Via Investor's Business Daily

Vertex Reports Third Quarter 2024 Financial Results

November 04, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗

November 04, 2024

A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.

Via Talk Markets

Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday? ↗

November 04, 2024

The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of Election Day on Tuesday.

Via Benzinga

Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts? ↗

November 04, 2024

VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock faces bearish trend.

Via Benzinga

Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers ↗

November 02, 2024

It won't be able to be profitable without hitting its targets for both of these figures.

Via The Motley Fool

As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report ↗

November 01, 2024

Amid the election, and a Fed rate vote, earnings season roars ahead.

Via Investor's Business Daily

Topics Economy Stocks

Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies' ↗

October 31, 2024

Mad Money's Jim Cramer recommends buying T. Rowe Price Group. "I think it's such a great company," he added.

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.